Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Scibase Holding

0.38

 

SEK

Less than 1K followers

SCIB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus
Compare
-4.76%
-0.26%
-1.55%
-7.32%
-2.56%
+18.75%
-90.9%
-82.52%
-98.65%

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

Read more
Market cap
128.55M SEK
Turnover
-
Revenue
29.71M
EBIT %
-226.09 %
P/E
-
Dividend yield-%
-
Latest research

Latest analysis report

Released: 02.12.2024

Latest extensive report

Released: 01.02.2024

Financial calendar
19.8
2025

Interim report Q2'25

7.11
2025

Interim report Q3'25

All
Research
Webcasts
Press releases
ShowingAll content types
Press release5/27/2025, 11:00 AM

SciBase reaches milestone with over 300,000 patients tested with Nevisense

Scibase Holding
Regulatory press release5/23/2025, 1:00 PM

SciBase publishes the Annual report for 2024

Scibase Holding
Press release5/20/2025, 8:29 PM

Redeye: Scibase Q1 - Laying the groundwork for US expansion

Scibase Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/14/2025, 1:00 PM

SciBase: Notice to attend the annual general meeting in Scibase Holding AB (publ)

Scibase Holding
Regulatory press release5/13/2025, 6:00 AM

SciBase: Interim report

Scibase Holding
Press release4/11/2025, 1:30 PM

SciBase launches next generation Nevisense

Scibase Holding
Press release2/26/2025, 8:18 AM

Redeye: SciBase Q4’2024 - Investing in US growth

Scibase Holding
Regulatory press release2/25/2025, 7:00 AM

SciBase: Year-end report

Scibase Holding
Press release2/21/2025, 7:00 AM

SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists

Scibase Holding
Press release1/30/2025, 12:00 PM

SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection

Scibase Holding
Press release1/28/2025, 7:00 AM

SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions

Scibase Holding
Regulatory press release1/27/2025, 7:00 AM

SciBase: Recalculation of warrants of series TO 2 following rights issue

Scibase Holding
Press release1/23/2025, 3:30 PM

SciBase: Nevisense (EIS) included in updated German (S1) imaging guidelines.

Scibase Holding
Regulatory press release1/14/2025, 5:00 PM

SciBase announces final outcome of directed issue and rights issue

Scibase Holding
Regulatory press release1/13/2025, 7:00 PM

SciBase announces outcome of directed issue and preliminary outcome of rights issue

Scibase Holding
Press release1/3/2025, 7:00 AM

SciBase: The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot

Scibase Holding
Press release12/27/2024, 7:00 AM

Today the subscription period in SciBase rights issue begins

Scibase Holding
Press release12/20/2024, 12:15 PM

SciBase letter from the CEO

Scibase Holding
Regulatory press release12/20/2024, 12:00 PM

SciBase publishes prospectus

Scibase Holding
Regulatory press release12/13/2024, 10:00 AM

Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)

Scibase Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team